Novo Nordisk headquarters building symbolizing MASH treatment innovation

INNOVATION

14 Nov 2025

Novo Sparks a New Fight to Fix MASH

Novo’s Akero buy raises the stakes in MASH as investors await key fibrosis data

Close-up illustration of an RNA strand in a biomedical research concept.

INSIGHTS

10 Nov 2025

Lilly’s New RNAi Partner Aims for Two Doses a Year

Eli Lilly and SanegeneBio team up to create long-acting RNAi drugs for obesity and diabetes

Two Victoza liraglutide injection pens displayed on a light wooden surface.

MARKET TRENDS

2 Sep 2025

First Generic GLP-1 for Weight Loss Sparks New Battle in US Market

Teva's launch of a Saxenda copy shakes up pricing power, forcing Novo and Lilly to rethink access and affordability.

White Novo Nordisk flags wave on tall poles against a cloudy sky, representing the company’s global presence.

PARTNERSHIPS

29 Aug 2025

Novo Nordisk Bets $550M on RNA's Next Act

Novo Nordisk partners with Replicate Bioscience to develop RNA-based obesity therapies, aiming to evolve beyond current GLP-1 blockbusters...

Smartphone showing glucose tracking app beside an arm-worn glucose sensor.

TECHNOLOGY

21 Aug 2025

AI Joins the Fight Against Obesity

FDA clears Dexcom and Signos tools as insurers and clinicians weigh digital alternatives to costly weight-loss drugs

Close-up of Wegovy semaglutide injection pens arranged in rows.

REGULATORY

17 Aug 2025

Conditional FDA Approval Puts Wegovy on Watch

US regulator clears Novo Nordisk drug for MASH, but continued approval to depend on long-term trial data

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.